CSI Market
Sign In | Register

Nanobiotix S a (NBTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NBTX Annual Cash Flow →
Quarterly cash flow trends provide additional context on Nanobiotix S a's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-26.84
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Gain Loss On Disposals PropertyPlant And Equipment0.17
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Provisions-
Adjustments For Sharebased Payments-
Adjustments For Finance Costs-
Adjustments For U S Initial Public Offering2018 Costs Offset-
Adjustments For Increase Decrease In Deferred Income-
Other Adjustments For Noncash Items-
Cash Flows From Used In Operations Before Changes In Working Capital-
Adjustments For Decrease Increase In Receivables From Taxes Other Than Income Tax-
Adjustments For Decrease Increase In Other Receivables-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Other Current Liabilities-
Increase Decrease In Working Capital-
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities-0.01
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable0.94
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities20.46
Discontinued operations0.00
Net Cash flow from Operating Activities-37.43
Investing Activities
Capital Expenditures-0.60
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchase Of Other Longterm Assets Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.01
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.65
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net38.53
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities41.91
Effect of exchange rate on cash flow-0.45
Discontinued operations0.00
Free Cash Flow-38.04
Total Cash Flow55.71
4 historic quarters locked

Sign in to unlock the full Nanobiotix S a cash flow history.

Sign In Create Free Account

About Nanobiotix S A Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 31, 2026
  • Source: nbx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001760854-26-000003

Figures are derived from filed reports and may be restated. Historical data is subject to revision.